Physician profile
Max Noah Chikovsky
NPI 1952832883
$1,979.81
in general payments reported to CMS, 2019-2025
17 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2021: $39.54 · 2022: $242 · 2023: $534 · 2024: $256 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $658.50 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $299.18 | 2023-2025 | Durysta, Ozurdex |
| Bausch & Lomb Americas INC. | $278.77 | 2022-2025 | Miebo, Xiidra, Xipere |
| Mallinckrodt Hospital Products INC. | $142.82 | 2022 | |
| Ani Pharmaceuticals, INC. | $126.50 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Alimera Sciences, INC. | $111.36 | 2022-2024 | Yutiq, Iluvien |
| Alcon Vision LLC | $82.63 | 2022-2025 | Rocklatan |
| Aerie Pharmaceuticals, INC. | $39.54 | 2021 | |
| Eyepoint US, INC. | $34.93 | 2022 | |
| Apellis Pharmaceuticals, INC. | $31.45 | 2025 | Syfovre |
| Dompe US, INC. | $30.72 | 2025 | Oxervate |
| Astellas Pharma US INC | $30.00 | 2025 | Izervay |
| Genentech USA, INC. | $28.35 | 2024 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $23.30 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $21.63 | 2023 | Tyrvaya |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.64 | 2023 | |
| Rxsight INC | $19.49 | 2024 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Chikovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.